We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > IL-17A

News List

CHMP recommends approval of UCB’s Bimzelx for plaque psoriasis pharmatimes
June 29, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval for UCB’s Bimzelx as a treatment for moderate-to-severe plaque psoriasis.
Focusing on Interior and Exterior: the Chinese Psoriasis Drug Market to Usher in a Great Change Miling
October 25, 2019
Eli Lilly announced on Sep. 4 that its new psoriasis drug: ixekizumab (Taltz®) had entered China and passed the marketing approval of the NMPA, which is another blockbuster psoriasis drug approved following the approval of the “first-in-class” new drug be
FDA approves the inclusion of new evidence for Cosentyx in PsA europeanpharmaceuticalreview
April 25, 2019
The FDA has approved the inclusion of new evidence that Cosentyx significantly slows the progression of joint structural damage...